Dec 23, 2022
The top ten stories of the year plus a few honorary mentions. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic
I Annual Wrap Ups on Medscape
- Mandrola’s Top 10 Cardiology Stories of 2022 https://www.medscape.com/viewarticle/985607
- 2022 in Review Through a Cardiology Lens https://www.medscape.com/viewarticle/984505
- Top Cardiology Trials of 2022 https://www.medscape.com/viewarticle/985647
II REVIVED BCIS2
- Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction https://www.nejm.org/doi/full/10.1056/nejmoa2206606
- PCI Fails in Stable Disease Again: REVIVED-BCIS https://www.medscape.com/viewarticle/979862
- PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 https://www.medscape.com/viewarticle/979853
III GUIDE HF
- Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01754-2
- CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO https://www.medscape.com/viewarticle/970278
- GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure https://www.medscape.com/viewarticle/957390
IV DECAAF II
- Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation The DECAAF II Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2793452
- DECAAF II: AF, Fibrosis Ablation Technique Falls Short, but Signs of Hope https://www.medscape.com/viewarticle/957469
V DANCAVAS
- Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2208681
- DANCAVAS Misses Primary Endpoint but Hints at Benefit from Comprehensive CV Screening https://www.medscape.com/viewarticle/979854
- Judicious CVD Screening May Work in Men: DANCAVAS https://www.medscape.com/viewarticle/980153
- DANCAVAS: Might Cardiovascular Screening Extend Men's Lives? https://www.medscape.com/viewarticle/979632
VI SODIUM HF
- Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial https://doi.org/10.1016/S0140-6736(22)00369-5
- Low-Sodium Diet Did Not Cut Clinical Events in Heart Failure Trial https://www.medscape.com/viewarticle/971482
- Sodium Restriction in Heart Failure: Another Dogma Felled by Randomization https://www.medscape.com/viewarticle/971697
- SODIUM-HF Simplifies Message to Patients on Diet https://www.medscape.com/viewarticle/971547
VII STRONG-HF
- Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial https://doi.org/10.1016/S0140-6736(22)02076-1
- Rapidly, Fully Optimize HF Meds After Hospital Discharge: STRONG-HF https://www.medscape.com/viewarticle/983870
- STRONG HF: More Beats Less After Discharge for Heart Failure https://www.medscape.com/viewarticle/983698
VIII Health Insurance Access
- Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status https://doi.org/10.1001/jamacardio.2022.1282
- Medicaid Expansion: Good First Step, but No Panacea for CV Care https://www.medscape.com/viewarticle/975141
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller
and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of
Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net